The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 μg/day and 100 μg/day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.
Bibliographical noteFunding Information:
This work was supported by a grant from the Glaxo Research Institute. The authors thank Joseph De Veaugh-Geiss, M.D., Alan Metz, M.D., Frank Stallone, Ph.D., and Joanne Cedrone, R.N., M.A., for their contributions to this study.